Candel Therapeutics (CADL)
8.38
+0.01 (0.12%)
Upcoming Events
Latest Headlines
Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
October 22, 2026 8:05 AM - StreetInsider
Jefferies Starts Candel Therapeutics Inc. (CADL) at Buy
October 22, 2026 4:20 AM - StreetInsider
Form 4 Candel Therapeutics, For: Sep 30 Filed by: Loggia Nicoletta
October 2, 2026 5:58 PM - SEC Filing
Form 4 Candel Therapeutics, For: Sep 30 Filed by: PAPA JOSEPH C
October 2, 2026 5:57 PM - SEC Filing
Form 4 Candel Therapeutics, For: Sep 30 Filed by: Manning Paul B
October 2, 2026 5:55 PM - SEC Filing
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
October 2, 2026 9:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
October 2, 2026 6:58 AM - StreetInsider
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026 4:05 PM - StreetInsider
Candel Therapeutics publishes phase 2a NSCLC trial data in peer-reviewed journal
October 1, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with
October 1, 2026 8:05 AM - StreetInsider
Candel Therapeutics reports immune activation data for prostate cancer drug
September 30, 2026 8:35 AM - StreetInsider
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Can
September 30, 2026 8:30 AM - StreetInsider
Candel Therapeutics reports immune data for prostate cancer drug at ASTRO
September 30, 2026 8:06 AM - StreetInsider
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
September 30, 2026 8:05 AM - StreetInsider
BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy
September 21, 2026 6:39 AM - StreetInsider
Form 4 Candel Therapeutics, For: Sep 10 Filed by: Tak Paul Peter
September 11, 2026 6:12 PM - SEC Filing
Form 144 Candel Therapeutics, Filed by: Tak Paul Peter
September 10, 2026 4:39 PM - SEC Filing
Form 4 Candel Therapeutics, For: Sep 08 Filed by: Zimmermann Martine
September 10, 2026 4:24 PM - SEC Filing
Form 3 Candel Therapeutics, For: Sep 08 Filed by: Zimmermann Martine
September 10, 2026 4:22 PM - SEC Filing
Form 8-K Candel Therapeutics, For: Sep 06
September 10, 2026 8:16 AM - SEC Filing
Candel Therapeutics adds regulatory veteran to its board
September 10, 2026 8:05 AM - StreetInsider
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
September 10, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 1, 2026 4:05 PM - StreetInsider
Candel Therapeutics to Present at September Investor Conferences
August 26, 2026 8:05 AM - StreetInsider
Form 4 Candel Therapeutics, For: Aug 17 Filed by: Tyagarajan Seshu
August 19, 2026 4:30 PM - SEC Filing
Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu
August 17, 2026 4:37 PM - SEC Filing
Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
August 17, 2026 12:22 PM - StreetInsider
Candel Therapeutics Inc. (CADL) PT Raised to $12 at BofA Securities
August 14, 2026 5:18 AM - StreetInsider
Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
August 13, 2026 8:58 AM - StreetInsider
Form 10-Q Candel Therapeutics, For: Jun 30
August 13, 2026 8:31 AM - SEC Filing
Form 8-K Candel Therapeutics, For: Aug 13
August 13, 2026 8:15 AM - SEC Filing
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
August 13, 2026 8:05 AM - StreetInsider
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 3, 2026 4:05 PM - StreetInsider
Candel Therapeutics to present prostate cancer data at ASTRO 2026
August 3, 2026 8:05 AM - StreetInsider
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
August 3, 2026 8:05 AM - StreetInsider
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
July 29, 2026 8:05 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
July 29, 2026 6:52 AM - StreetInsider
Form SCHEDULE 13G Candel Therapeutics, Filed by: BlackRock, Inc.
July 27, 2026 4:28 PM - SEC Filing
Full Article List
